期刊
CANCER TREATMENT REVIEWS
卷 63, 期 -, 页码 40-47出版社
ELSEVIER SCI LTD
DOI: 10.1016/j.ctrv.2017.11.007
关键词
CXCL9; CXCL10; CXCL11; CXCR3; Cancer; Immunotherapy
类别
资金
- Uehara Memorial Foundation
- Swiss Cancer League [BIL KLS-333402 2014]
- Werner and Hedy Berger-Janser Foundation for cancer research
- NIH [P30CA014089-27S1]
- Gloria Borges Wunderglo Project
- Dhont Family Foundation
- Daniel Butler Research Fund
Chemokines are proteins which induce chemotaxis, promote differentiation of immune cells, and cause tissue extravasation. Given these properties, their role in anti-tumor immune response in the cancer environment is of great interest. Although immunotherapy has shown clinical benefit for some cancer patients, other patients do not respond. One of the mechanisms of resistance to checkpoint inhibitors may be chemokine signaling. The CXCL9, -10, -11/CXCR3 axis regulates immune cell migration, differentiation, and activation, leading to tumor suppression (paracrine axis). However, there are some reports that show involvements of this axis in tumor growth and metastasis (autocrine axis). Thus, a better understanding of CXCL9, -10, -11/CXCR3 axis is necessary to develop effective cancer control. In this article, we summarize recent evidence regarding CXCL9, CXCL10, CXCL11/CXCR3 axis in the immune system and discuss their potential role in cancer treatment. (C) 2017 Elsevier Ltd. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据